Theranexus (EPA:ALTHX)

BRIEF

published on 06/09/2026 at 08:05, 3 months 4 days ago

Industry stakeholders united to raise awareness of Batten disease

Partnership Clinical Study Awareness Batten Disease THX Pharma
PRESS RELEASE

published on 06/09/2026 at 08:00, 3 months 4 days ago

THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day
Join THX Pharma, Biocodex, and BBDF as Platinum Sponsors at the 2026 BDSRA Family Conference to provide an update on the Batten-1 program and Phase 3 study for CLN3 Batten disease

BBDF THX Pharma Biocodex Batten-1 Program Platinum Sponsors
BRIEF

published on 04/28/2026 at 19:05, 4 months 14 days ago

THX Pharma Strengthens Financial Position in 2025

Financial Results Cash Position Neurological Diseases THX Pharma Biocodex Partnership
BRIEF

published on 04/28/2026 at 19:05, 4 months 14 days ago

THX Pharma: Annual Results and Cash Flow Statement

2025 Annual Results THX Pharma Biocodex Cash Flow 2026 Strategic Licenses
PRESS RELEASE

published on 04/28/2026 at 19:00, 4 months 14 days ago

THX Pharma Publishes Its 2025 Annual Results, Cash Position as of March 31, 2026, and Provides a Business Update
THX Pharma announces annual results, cash position, and strategic partnerships, including Biocodex agreement. Financial stability secured. Focus on clinical development and commercialization of TX01 and Batten-1

Strategic Partnership Financial Stability Neurological Diseases THX Pharma Biocodex
BRIEF

published on 03/25/2026 at 18:50, 5 months 18 days ago

THX Pharma Publishes Letter to Shareholders

Innovation Shareholders Licensing Agreements Neurological Diseases THX Pharma
BRIEF

published on 03/25/2026 at 18:50, 5 months 18 days ago

Theranexus publishes its letter to shareholders

Shareholders Biopharmaceutical Neurology Theranexus Drugs
PRESS RELEASE

published on 03/25/2026 at 18:45, 5 months 18 days ago

THX Pharma Announces the Publication of its Letter to Shareholders
THX Pharma (Theranexus) announces the publication of a letter to shareholders regarding its innovative treatments for rare neurological diseases. Company details and contact information included

Shareholders Biopharmaceutical Theranexus Neurological Diseases THX Pharma
BRIEF

published on 02/25/2026 at 18:05, 6 months 15 days ago

THX Pharma increases the resources of its liquidity contract

Liquidity Contract Euronext Growth Biopharmaceutical Financial Resources THX Pharma
BRIEF

published on 02/19/2026 at 18:05, 6 months 21 days ago

THX Pharma Announces Strong Cash Position at Year-End

Cash Position THX Pharma Biocodex Agreement Batten-1 Program TX01 Development

Published on 09/12/2026 at 02:35, 1 day 6 hours ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 10 hours ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 1 day 11 hours ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 1 day 12 hours ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 16 hours ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

Published on 09/12/2026 at 17:50, 15 hours 41 minutes ago

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 2 hours ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 11 hours ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 11 hours ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 13 hours ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031

View all EQS

Published on 09/11/2026 at 07:00, 2 days 2 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 2 days 2 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 2 days 14 hours ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 3 days 2 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 3 days 14 hours ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News